Initial evaluation of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (FSPG) PET/CT imaging in patients with head and neck cancer, colorectal cancer, or non-Hodgkin lymphoma

EJNMMI Research

Table 1 Demographic information for the 15 human participants imaged with [¹⁸F]FSPG PET

Patient	Gender	Age	Pathology	Prior treatment (months before)
1	Male	44	HNC, SCC; nasal cavity	None
2	Male	73	HNC, SCC; recurrent (oropharynx-oral cavity)	Chemoradiation, laryngectomy (156)
3	Male	71	HNC, SCC; left maxillary sinus	Chemoradiation (3.5)
4	Male	74	HNC, SCC; larynx	None
5	Male	72	HNC, SCC; nasopharynx	None
6	Male	62	CRC, adenocarcinoma	Hemicolectomy (36), chemotherapy (6)
7	Male	64	CRC, adenocarcinoma	Hemicolectomy (16), chemotherapy (9)
8	Male	69	CRC, adenocarcinoma	Chemoradiation (6)
9	Female	50	CRC, adenocarcinoma	Chemotherapy neoadjuvant and rectosigmoid resection (26), chemotherapy (17)
10	Male	69	CRC, adenocarcinoma	None
11	Male	72	NHL, DLBCL	Chemoradiation (10), chemotherapy (0.5)
12	Female	78	NHL, mantle cell	None
13	Male	65	NHL, mantle cell	Chemotherapy (5)
14	Male	87	NHL, follicular	None
15	Female	43	NHL, cutaneous T-cell	None